Cooper Companies (COO) Projected to Announce Quarterly Earnings on Wednesday

Key Points

• Cooper Companies is expected to report Q3 2026 results after market close on September 9. Analysts forecast earnings of $1.12 per share on $1.098 billion in revenue, while the company’s FY 2026 EPS guidance is $4.58–$4.66.
• The company’s prior quarter exceeded expectations, with EPS of $1.21 versus the $1.10 consensus and revenue of $1.08 billion, up 7.9% year over year.
• COO shares recently traded at $69.28, down 1.2%, and analysts maintain a consensus “Hold” rating with an $81.64 price target; recent target changes were mixed, ranging from $66 to $86.

Cooper Companies (NASDAQ:COO - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Wednesday, September 9th. Analysts expect Cooper Companies to post earnings of $1.12 per share and revenue of $1.0984 billion for the quarter. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Interested persons may visit the the company's upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Wednesday, September 9, 2026 at 5:00 PM ET.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its earnings results on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the business earned $0.96 EPS. The business's quarterly revenue was up 7.9% compared to the same quarter last year. On average, analysts expect Cooper Companies to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Cooper Companies Trading Down 1.2%

NASDAQ COO opened at $69.28 on Wednesday. The firm has a market capitalization of $13.51 billion, a PE ratio of 58.71, a price-to-earnings-growth ratio of 1.83 and a beta of 0.82. The business's 50-day moving average price is $72.72 and its two-hundred day moving average price is $70.63. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. Cooper Companies has a 12 month low of $58.89 and a 12 month high of $89.83.

Analyst Ratings Changes

A number of equities analysts recently commented on COO shares. Stifel Nicolaus cut their price objective on Cooper Companies from $95.00 to $85.00 and set a "buy" rating on the stock in a research note on Friday, June 5th. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $80.00 to $71.00 and set a "neutral" rating for the company in a research report on Friday, June 5th. Needham & Company LLC lowered their price target on shares of Cooper Companies from $101.00 to $86.00 and set a "buy" rating for the company in a report on Friday, June 5th. Citigroup reaffirmed a "neutral" rating and issued a $80.00 price objective (up from $76.00) on shares of Cooper Companies in a research note on Thursday, August 13th. Finally, Wells Fargo & Company reiterated a "sell" rating and set a $66.00 price objective (down from $82.00) on shares of Cooper Companies in a research report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $81.64.

Institutional Investors Weigh In On Cooper Companies

Several large investors have recently added to or reduced their stakes in COO. Axxcess Wealth Management LLC boosted its holdings in shares of Cooper Companies by 37.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 9,980 shares of the medical device company's stock worth $818,000 after buying an additional 2,698 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Cooper Companies by 17.0% during the 4th quarter. Corient Private Wealth LLC now owns 25,699 shares of the medical device company's stock worth $2,106,000 after buying an additional 3,738 shares during the period. Alberta Investment Management Corp bought a new stake in shares of Cooper Companies in the 4th quarter valued at $1,582,000. Mercer Global Advisors Inc. ADV increased its stake in shares of Cooper Companies by 94.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 17,893 shares of the medical device company's stock valued at $1,466,000 after acquiring an additional 8,707 shares in the last quarter. Finally, Vident Advisory LLC lifted its position in shares of Cooper Companies by 476.6% during the 4th quarter. Vident Advisory LLC now owns 52,152 shares of the medical device company's stock valued at $4,274,000 after acquiring an additional 43,108 shares during the period. Institutional investors and hedge funds own 24.39% of the company's stock.

About Cooper Companies

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source